Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia (Q35589778)
Jump to navigation
Jump to search
scientific article published on 31 July 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia |
scientific article published on 31 July 2011 |
Statements
1 reference
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia (English)
1 reference
Ali Taher
1 reference
Mohsen S Elalfy
1 reference
Kusai Al Zir
1 reference
Shahina Daar
1 reference
Abdullah Al Jefri
1 reference
Dany Habr
1 reference
Ulrike Kriemler-Krahn
1 reference
Ali El-Ali
1 reference
Bernard Roubert
1 reference
Amal El-Beshlawy
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference